The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD Announces Interim Safety and Efficacy Data from Pivotal Ponatinib PACE Trial to Be Presented at Annual American Society of Hematology Meeting

<p class='bwalignc'> <i>~ Ponatinib to be Featured in Fourteen Presentations</i> </p> <p class='bwalignc'> <i>~ Company to Host Investor Meeting and Webcast with Dr. Moshe Talpaz on Monday, December 12 at 7 a.m (PST)</i> </p>

Thursday, November 17, 2011

ARIAD Announces Interim Safety and Efficacy Data from Pivotal Ponatinib PACE Trial to Be Presented at Annual American Society of Hematology Meeting07:35 EST Thursday, November 17, 2011 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that interim clinical data from the fully enrolled, pivotal PACE trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 53rd Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, December 10-13, 2011. The interim findings from the PACE trial will be featured in an oral presentation on Sunday, December 11 and also will be highlighted in an investor meeting to be webcast live from San Diego. This trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to either nilotinib or dasatinib, two currently available CML therapies, or those who have the T315I mutation of BCR-ABL for which no current treatments are known to be effective. Thirteen additional abstracts describing clinical and non-clinical work on ponatinib will also be presented at the meeting. Oral Presentation of Interim Data from PACE Trial Title:   Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation Oral Session: Chronic Myeloid Leukemia – Therapy: Resistance to Tyrosine Kinase Inhibitors Date & Time: Sunday, December 11, 2011, 4:30 p.m. (PST) Abstract No.: 109 Presenter: Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center) Location: Ballroom 20BC Investor Meeting and Webcast A breakfast meeting to review the interim PACE trial data with research analysts and institutional investors will feature Moshe Talpaz, M.D., Associate Director of Translational Research and Associate Chief of Hematologic Malignancies, Trotman Professor of Leukemia Research at the University of Michigan Medical Center, and members of ARIAD's management. Dr. Talpaz has been an investigator in the Phase 1 and Phase 2 trials of ponatinib. This meeting will be webcast live and can be accessed by visiting the investor relations section of the Company's website at investor.ariad.com or dialing: 866.770.7125 (domestic) or 617.213.8066 (international) and providing the pass code 91497220. Date:   Monday, December 12, 2011   Time: 7:00 a.m. to 8:00 a.m. (PST)   Location: The Westin Gaslamp Quarter Hotel, Santa Fe Conference Room To attend the meeting, please RSVP to Investor.breakfast@ariad.com by Wednesday, December 7, 2011. A replay of this investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived for four weeks. To ensure a timely connection to the live webcast, participants should log onto the webcast at least 15 minutes prior to the scheduled start time. The following presentations are included among the 14 presentations at ASH to feature clinical and non-clinical data on ponatinib. Title:   Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies Oral Session: Chronic Myeloid Leukemia – Therapy: New Drugs, New Procedures Date & Time: Monday, December 12, 2011, 3:00 p.m. (PST) Abstract No.: 602 Presenter: Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center) Location: Ballroom 20BC   Title: ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib Poster Session: Chronic Myeloid Leukemia – Biology and Pathophysiology, Excluding Therapy: Poster II Date & Time: Sunday, December 11, 2011, 6:00 – 8:00 p.m. (PST) Abstract No.: 2745 Presenter: Deborah White, Ph.D. (University of Adelaide, Australia) Location: Hall GH   Title: Ponatinib Is Active Against the CUX1-FGFR1 Fusion Kinase and Against Imatinib Resistance Mutations of the FIP1L1-PDGFRα Fusion Kinase and of KIT Poster Session: Myeloproliferative Syndromes: Poster III Date & Time: Monday, December 12, 2011, 6:00 – 8:00 p.m. (PST) Abstract No.: 3848 Presenter: Els Lierman, Ph.D. (Center for Human Genetics, Katholieke Universiteit Leuven, Belgium) Location: Hall GH   Title: Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutations Oral Session: Molecular Pharmacology, Drug Resistance: Targeting Chemoresistant Cells and Niche Date & Time: Tuesday, December 13, 2011, 8:45 a.m. (PST) Abstract No.: 930 Presenter: Catherine C. Smith, M.D. (The University of California San Francisco) Location: Room 25 About ARIAD ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit http://www.ariad.com. ARIAD Pharmaceuticals, Inc.For InvestorsMaria E. Cantor, 617-621-2208Maria.cantor@ariad.comorFor MediaLiza Heapes, 617-621-2315Liza.heapes@ariad.com